Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 3
2012 4
2013 12
2014 13
2015 12
2016 15
2017 11
2018 10
2019 20
2020 15
2021 1
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 32444370

94 results
Results by year
Filters applied: . Clear all
Page 1
64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection.
Loft M, Carlsen EA, Johnbeck CB, Johannesen HH, Binderup T, Pfeifer A, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A. Loft M, et al. J Nucl Med. 2021 Jan;62(1):73-80. doi: 10.2967/jnumed.120.244509. Epub 2020 May 22. J Nucl Med. 2021. PMID: 32444370
Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A. Johnbeck CB, et al. J Nucl Med. 2017 Mar;58(3):451-457. doi: 10.2967/jnumed.116.180430. Epub 2016 Sep 22. J Nucl Med. 2017. PMID: 27660147 Free article. Clinical Trial.
Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A. Pfeifer A, et al. J Nucl Med. 2012 Aug;53(8):1207-15. doi: 10.2967/jnumed.111.101469. Epub 2012 Jul 10. J Nucl Med. 2012. PMID: 22782315 Free article. Clinical Trial.
64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.
Carlsen EA, Johnbeck CB, Binderup T, Loft M, Pfeifer A, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A. Carlsen EA, et al. J Nucl Med. 2020 Oct;61(10):1491-1497. doi: 10.2967/jnumed.119.240143. Epub 2020 Feb 28. J Nucl Med. 2020. PMID: 32111685
64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A. Pfeifer A, et al. J Nucl Med. 2015 Jun;56(6):847-54. doi: 10.2967/jnumed.115.156539. Epub 2015 May 7. J Nucl Med. 2015. PMID: 25952736 Free article.
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study.
Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, Jia R, Xu J, Huo L. Zhu W, et al. J Nucl Med. 2020 Jun;61(6):897-903. doi: 10.2967/jnumed.119.235093. Epub 2019 Nov 1. J Nucl Med. 2020. PMID: 31676731 Free PMC article.
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.
Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, Núñez R. Delpassand ES, et al. J Nucl Med. 2020 Jun;61(6):890-896. doi: 10.2967/jnumed.119.236091. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924723 Clinical Trial.
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients.
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. Pauwels E, et al. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046. doi: 10.1007/s00259-020-04918-4. Epub 2020 Jul 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32617641
The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.
Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z. Yu J, et al. Mol Imaging Biol. 2019 Oct;21(5):984-990. doi: 10.1007/s11307-019-01328-3. Mol Imaging Biol. 2019. PMID: 30796708
68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP. Etchebehere EC, et al. J Nucl Med. 2014 Oct;55(10):1598-604. doi: 10.2967/jnumed.114.144543. Epub 2014 Aug 28. J Nucl Med. 2014. PMID: 25168627 Free article.
94 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page